Research dossier
DSIP — dossier on a nonapeptide with no identified receptor
A nonapeptide isolated for an observed effect before its receptor was identified.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 62568-57-4 |
| Molar mass | 848.81 g/mol |
| Molecular formula | C₃₅H₄₈N₁₀O₁₅ |
| Sequence / nature | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
This peptide illustrates an instructive case in pharmacology: an activity observed and named before a mechanism was established, and which has remained so decades later. Its present interest is partly historiographical — it documents the limits of effect-guided isolation approaches.
Mechanism studied
DSIP (delta sleep-inducing peptide) is a nonapeptide initially isolated from rabbit blood, on the basis of an observed electroencephalographic activity. Its name reflects that functional origin, not an established mechanism.
That is its most notable feature for research: several decades after its isolation, no specific receptor has been identified and characterised by consensus. The literature mentions interactions with various neurotransmission systems — GABAergic, opioid, glutamatergic — without a binding site of its own having been demonstrated.
The in-vitro work reported covers measurements of neurotransmitter release in synaptosome preparations, competitive binding assays that did not reveal a high-affinity site, and enzymatic stability analyses showing rapid degradation in the presence of serum.
This absence of an identified target is a major limit for the design of mechanistic experiments.
In-vitro literature
The body of work is old and heterogeneous, with methodologies predating current standards in receptor pharmacology. Modern replication attempts are few.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
The name evokes a historically observed function, not an established mechanism. This point should be explicit in any presentation of the compound.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Methodological limits
The absence of an identified receptor is the dominant limit: without a molecular target, no classical pharmacology experiment — dose-response curve, competitive displacement, antagonism — can be designed discriminatingly. Rapid degradation in the presence of serum also makes it necessary to control the real duration of exposure, often well below the nominal duration of the assay.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
An unmodified nonapeptide. Rapid degradation in serum-containing medium is documented and should be taken into account in prolonged exposure protocols.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
| 15mg | 15.00 mg/ml | 7.50 mg/ml | 5.00 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
- 15mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 15mg | Covered | In stock |
| 10mg | Covered | In stock |
| The verification programme covers exclusively the identity and purity of the material, by reverse-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic. |
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.